179 related articles for article (PubMed ID: 25267750)
21. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
[TBL] [Abstract][Full Text] [Related]
22. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
23. [Sunitinib-induced pyoderma gangrenosum].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
[No Abstract] [Full Text] [Related]
24. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
[No Abstract] [Full Text] [Related]
25. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
O'Donnell PH
BJU Int; 2011 Oct; 108(8):1284-5. PubMed ID: 21418138
[No Abstract] [Full Text] [Related]
26. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
28. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
[No Abstract] [Full Text] [Related]
29. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Becze E
ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
[No Abstract] [Full Text] [Related]
30. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
31. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
32. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
33. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
34. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Garfield DH; Hercbergs A; Davis PJ
J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
[No Abstract] [Full Text] [Related]
35. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
[TBL] [Abstract][Full Text] [Related]
36. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
Rolleman EJ; Weening J; Betjes MG
Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
[No Abstract] [Full Text] [Related]
37. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
39. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
[No Abstract] [Full Text] [Related]
40. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Gschwend J; Keilholz U
Aktuelle Urol; 2011 Jul; 42(4):242-6. PubMed ID: 21720974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]